美国联合医疗(United Therapeutics)近日披露了其创新药物Miroliverelap®针对急性肝衰竭患者的一期临床试验数据,结果显示疗效积极。该研究评估了药物的安全性与耐受性,初步数据表明患者肝功能指标呈现改善趋势,未出现严重不良反应。这一突破为后续临床研究奠定了基础,有望为急性肝衰竭治疗提供新方案。
美国联合医疗(United Therapeutics)近日披露了其创新药物Miroliverelap®针对急性肝衰竭患者的一期临床试验数据,结果显示疗效积极。该研究评估了药物的安全性与耐受性,初步数据表明患者肝功能指标呈现改善趋势,未出现严重不良反应。这一突破为后续临床研究奠定了基础,有望为急性肝衰竭治疗提供新方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.